selected scholarly activity
-
conferences
- Abstract B096: Oncolytic vaccination for HPV induced cancer. Cancer immunology research. B096-B096. 2016
- USE OF ONCOLYTIC VIRAL VACCINES TO TREAT CANCER. Anticancer Research. 6029-6030. 2014
- Tumors adapt rapidly to thwart vaccine-induced T cell attack but this adaptive response can be overcome by manipulation of costimulation and immune checkpoints (48.30). Journal of Immunology. 48.30-48.30. 2011
- Investigating the Impact of Autophagy Modulation on Dendritic Cell Cancer Vaccines. Journal of immunotherapy (Hagerstown, Md. : 1997). 892-892. 2010
- F.116. Unravelling the Mechanism of Xenoimmunization By Epitope Mapping. Clinical Immunology. S91-S92. 2006
- DIFFERENTIAL EFFECTS OF DENDRITIC CELLS OVEREXPRESSING MAMMALIAN IL-10 ON ORGAN ALLOGRAFT AND ANTI-TUMOR IMMUNITY. Transplantation. S248-S248. 1999
- Adenovirus-transduced dendritic cells prime both CD8 class I and CD4 class II-restricted CTL via CD4-dependent mechanism.. Journal of Leukocyte Biology. 99-99. 1998
- Modulation of dendritic cell function and effects on allograft survival by TGF beta or IL-10 gene transduction. Journal of Leukocyte Biology. 40-40. 1998
- Isolation and characterization of cultured human dendritic cells: A potential target for adenoviral-based gene transfer of tumour peptides.. Blood. 4636-4636. 1997
- Intra-marrow administration of adenoviral vectors for localized cytokine delivery.. Blood. 1636-1636. 1995
-
journal articles
- Level of expression of MHCI-presented neoepitopes influences tumor rejection by neoantigen-specific CD8+ T cells.. Cancer immunology research. 2024
- The effect of comb length on the in vitro and in vivo properties of self-assembled poly(oligoethylene glycol methacrylate)-based block copolymer nanoparticles. Nanoscale Advances. 6:2487-2498. 2024
- Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells. Journal for ImmunoTherapy of Cancer. 12:e006781-e006781. 2024
- HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion. Clinical Cancer Research. 29:4289-4305. 2023
- Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells. Cancers. 15:1295-1295. 2023
- Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells. Science Translational Medicine. 15:eabq6024. 2023
- HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity. Journal of Clinical Investigation. 132:e159283. 2022
- IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity. Molecular Therapy - Oncolytics. 25:16-30. 2022
- Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell. 185:896-915.e19. 2022
- A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner. International Journal of Molecular Sciences. 23:1754-1754. 2022
- Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer. Cancers. 13:5590-5590. 2021
- Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells. Communications Biology. 4:859. 2021
- Functional Analysis of Tumor-Infiltrating Myeloid Cells by Flow Cytometry and Adoptive Transfer. Journal of Visualized Experiments. 2021. 2021
- A Transit Time-Resolved Microflow Cytometry-Based Agglutination Immunoassay for On-Site C-Reactive Protein Detection. Micromachines. 12:109-109. 2021
- A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy. Cytokine and Growth Factor Reviews. 56:149-159. 2020
- De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology. 3:645. 2020
- Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. Journal for ImmunoTherapy of Cancer. 8:e000981-e000981. 2020
- Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8+ T-cell memory development. Nature Cell Biology. 22:18-25. 2020
- Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation. 129:5400-5410. 2019
- Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. OncoImmunology. 8:e1512329. 2019
- Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. Journal of Clinical Investigation. 129:518-530. 2018
- Transforming the prostatic tumor microenvironment with oncolytic virotherapy. OncoImmunology. 7:e1445459-e1445459. 2018
- HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants. Cell Reports. 24:642-654. 2018
- Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine. 36:2181-2192. 2018
- A Pck1-directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells. Nature Cell Biology. 20:21-27. 2018
- Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virotherapy. Volume 7:117-128. 2018
- Customized Viral Immunotherapy for HPV-Associated Cancer. Cancer immunology research. 5:847-859. 2017
- Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. Acta Pharmaceutica Sinica B. 7:532-540. 2017
- Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines. 4:21-21. 2016
- Correction: Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathogens. 12:e1005706-e1005706. 2016
- Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination. Journal of Immunology. 196:4587-4595. 2016
- Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway. PLoS Pathogens. 12:e1005589-e1005589. 2016
- S6K-STING interaction regulates cytosolic DNA–mediated activation of the transcription factor IRF3. Nature Immunology. 17:514-522. 2016
- High Physiological Concentrations of Progesterone Reverse Estradiol-Mediated Changes in Differentiation and Functions of Bone Marrow Derived Dendritic Cells. PLoS ONE. 11:e0153304-e0153304. 2016
- T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Molecular Therapy. 23:1600-1610. 2015
- Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate immunity. 21:626-634. 2015
- Cell-free Tumor Microparticle Vaccines Stimulate Dendritic Cells via cGAS/STING Signaling. Cancer immunology research. 3:196-205. 2015
- Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virotherapy. 4:157-157. 2015
- Maraba Virus as a Potent Oncolytic Vaccine Vector. Molecular Therapy. 22:420-429. 2014
- Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Frontiers in Oncology. 4:145. 2014
- Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor. Molecular Therapy. 22:206-218. 2014
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines. OncoImmunology. 2:e26013-e26013. 2013
- Targeted Inhibition of Serotonin Type 7 (5-HT7) Receptor Function Modulates Immune Responses and Reduces the Severity of Intestinal Inflammation. Journal of Immunology. 190:4795-4804. 2013
- HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy. Molecular Therapy. 21:887-894. 2013
- Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8+ T-cell recall responses. Blood. 121:2432-2439. 2013
- Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. OncoImmunology. 1:419-431. 2012
- ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. Molecular Therapy. 20:1148-1157. 2012
- Combined mTOR Inhibition and OX40 Agonism Enhances CD8+ T Cell Memory and Protective Immunity Produced by Recombinant Adenovirus Vaccines. Molecular Therapy. 20:860-869. 2012
- Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines.. Molecular Therapy. 20:860-869. 2012
- Ad-hDCT (tumor vaccine) inhibiting the proliferation of intracranial B16 melanoma cells in C57BL/6 mice. Acta Anatomica Sinica. 42:787-791. 2011
- Engineering Dendritic Cells to Enhance Cancer Immunotherapy. Molecular Therapy. 19:841-853. 2011
- IL-15 and Type I Interferon Are Required for Activation of Tumoricidal NK Cells by Virus-Infected Dendritic Cells. Cancer Research. 71:2497-2506. 2011
- Tolerogenic dendritic cells and their potential applications. Immunology. 132:307-314. 2011
- Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy. Molecular Therapy. 19:335-344. 2011
- CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood. 117:1146-1155. 2011
- Potentiating Cancer Immunotherapy Using an Oncolytic Virus. Molecular Therapy. 18:1430-1439. 2010
- Processing of Tumor Antigen Differentially Impacts the Development of Helper and Effector CD4+ T-cell Responses. Molecular Therapy. 18:1224-1232. 2010
- Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen. Journal of Immunology. 184:4269-4275. 2010
- Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells. Cancer Immunology, Immunotherapy. 59:313-321. 2010
- Persistence of Transgene Expression Influences CD8+T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus. Journal of Virology. 83:12027-12036. 2009
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus. Molecular Therapy. 17:1814-1821. 2009
- Recombinant Vesicular Stomatitis Virus Transduction of Dendritic Cells Enhances Their Ability to Prime Innate and Adaptive Antitumor Immunity. Molecular Therapy. 17:1465-1472. 2009
- CD4+ T‐cell‐mediated anti‐tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. European Journal of Immunology. 39:1252-1259. 2009
- Neoadjuvant Vaccination Provides Superior Protection against Tumor Relapse following Surgery Compared with Adjuvant Vaccination. Cancer Research. 69:3979-3985. 2009
- High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Therapy. 16:338-350. 2009
- Mucosally Delivered Dendritic Cells Activate T Cells Independently of IL-12 and Endogenous APCs. Journal of Immunology. 181:2356-2367. 2008
- Culture of myeloid dendritic cells from bone marrow precursors. Journal of Visualized Experiments. 769. 2008
- Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments. Gut. 57:475-481. 2008
- Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells. Molecular Therapy. 16:411-418. 2008
- Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.. Molecular Therapy. 16:411-418. 2008
- Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Human Immunology. 69:32-40. 2008
- The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cellular Immunology. 250:55-67. 2007
- Antigen Presentation by Exosomes Released from Peptide-Pulsed Dendritic Cells Is not Suppressed by the Presence of Active CTL. Journal of Immunology. 179:5024-5032. 2007
- Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope. Cancer Research. 67:6459-6467. 2007
- On the Role of CD4+ T Cells in the CD8+ T-Cell Response Elicited by Recombinant Adenovirus Vaccines. Molecular Therapy. 15:997-1006. 2007
- On the role of CD4(+) T cells in the CD8(+) T-cell response elicited by recombinant adenovirus vaccines. Molecular Therapy. 15:997-1006. 2007
- Dose-effect relationship between Ad SIINFEKL-Luc immunization and the induced immune response. Chinese Journal of Microbiology and Immunology. 27:268-272. 2007
- [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity].. National Medical Journal of China. 87:399-403. 2007
- Cigarette Smoke Impairs NK Cell-Dependent Tumor Immune Surveillance. Journal of Immunology. 178:936-943. 2007
- [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].. Chinese Journal of Oncology. 28:658-661. 2006
- Development of Cell-Based Tuberculosis Vaccines: Genetically Modified Dendritic Cell Vaccine Is a Much More Potent Activator of CD4 and CD8 T Cells Than Peptide- or Protein-Loaded Counterparts. Molecular Therapy. 13:766-775. 2006
- Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia. Molecular Therapy. 13:270-279. 2006
- The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity. Journal of Immunology. 176:200-210. 2006
- Immunity against murine melanomas elicited by dendritic cells infected with adenovirus encoding human tyrosine-related protein 2. Chinese Journal of Microbiology and Immunology. 25:993-997. 2005
- Recent Advances in the Development of Adenovirus- and Poxvirus- Vectored Tuberculosis Vaccines. Current Gene Therapy. 5:485-492. 2005
- [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].. National Medical Journal of China. 85:1596-1600. 2005
- Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity?. Animal Health Research Reviews. 5:227-234. 2004
- T-cell-mediated inflammation does not contribute to the maintenance of airway dysfunction in mice. Journal of applied physiology. 97:2258-2265. 2004
- The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo. Vaccine. 22:2517-2523. 2004
- CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine. Journal of Immunology. 172:5200-5205. 2004
- Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin. Cancer Research. 64:1509-1514. 2004
- TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. Journal of Clinical Investigation. 113:401-413. 2004
- TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. Journal of Clinical Investigation. 113:401-413. 2004
- DetailedAnalysis of the CD8 + T-Cell Response followingAdenovirusVaccination. Journal of Virology. 77:13407-13411. 2003
- A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Therapy. 10:755-763. 2003
- Electroporation Enables Plasmid Vaccines to Elicit CD8+ T Cell Responses in the Absence of CD4+ T Cells. Journal of Immunology. 171:3379-3384. 2003
- Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine. 21:1363-1370. 2003
- Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Therapy. 10:251-260. 2003
- Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth. Gene Therapy. 9:898-905. 2002
- Adenoviral-Mediated Gene Transfer of Lymphotactin to the Lungs of Mice and Rats Results in Infiltration and Direct Accumulation of CD4+, CD8+, and NK Cells. Journal of Interferon and Cytokine Research. 22:573-582. 2002
- Miakron-2000 cetane-number-increasing additive for diesel fuels. Chemistry and Technology of Fuels and Oils (English translation of Khimiya i Tekhnologiya Topliv i Masel). 38:303-308. 2002
- The Economic Costs of Early Stage Prostate Cancer. PharmacoEconomics (Auckland). 20:869-878. 2002
- The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opinion on Biological Therapy. 2:75-85. 2002
- Dendritic Cell-Derived IL-12 Is Not Required for the Generation of Cytotoxic, IFN-γ-Secreting, CD8+ CTL In Vivo. Journal of Immunology. 167:5027-5033. 2001
- Genetically modified dendritic cells in cancer therapy: Implications for transfusion medicine. Transfusion Medicine Reviews. 15:292-304. 2001
- Role of Dendritic Cell-Derived Cytokines in Immune Regulation. Current Pharmaceutical Design. 7:977-992. 2001
- Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma - a phase 1 study. Leukemia. 15:846-854. 2001
- CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Dendritic cells expressing TGFβ/IL-10, and CHO cells with OX-2, increase graft survival. Transplantation Proceedings. 33:1565-1566. 2001
- Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Therapy. 8:316-323. 2001
- Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin‐10 on organ allograft and tumour rejection. Immunology. 101:233-241. 2000
- Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.. Cancer Research. 60:3247-3253. 2000
- Synergy in Induction of Increased Renal Allograft Survival after Portal Vein Infusion of Dendritic Cells Transduced to Express TGFβ and IL-10, along with Administration of CHO Cells Expressing the Regulatory Molecule OX-2. Clinical Immunology. 95:182-189. 2000
- Enhanced Immune Response to the Melanoma Antigen gp100 Using Recombinant Adenovirus-Transduced Dendritic Cells. Cellular Immunology. 198:131-138. 1999
- Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors. Journal of Virology. 73:8027-8034. 1999
- Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression.. International Journal of Oncology. 14:771-776. 1999
- Adenoviral Vectors Expressing Lymphotactin and Interleukin 2 or Lymphotactin and Interleukin 12 Synergize to Facilitate Tumor Regression in Murine Breast Cancer Models. Human gene therapy. Clinical development. 10:697-709. 1999
- Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Therapy. 6:350-363. 1999
- Enhancement of dendritic cell tolerogenicity by genetic modification using adenoviral vectors encoding cDNA for TGFβ1. Transplantation Proceedings. 31:1195-1195. 1999
- PHENOTYPE, FUNCTION, AND IN VIVO MIGRATION AND SURVIVAL OF ALLOGENEIC DENDRITIC CELL PROGENITORS GENETICALLY ENGINEERED TO EXPRESS TGF-??1,2. Transplantation. 66:1810-1817. 1998
- Enhanced Interleukin-2 Gene Transfer Immunotherapy of Breast Cancer by Coexpression of B7-1 and B7-2. Journal of Interferon and Cytokine Research. 18:927-937. 1998
- ENHANCEMENT OF DENDRITIC CELL TOLEROGENICITY BY GENETIC MODIFICATION USING ADENOVIRAL VECTORS ENCODING cDNA FOR TGF??1. Transplantation. 65:S22-S22. 1998
- ENHANCEMENT OF DENDRITIC CELL TOLEROGENICITY BY GENETIC MODIFICATION USING ADENOVIRAL VECTORS ENCODING cDNA FOR TGFβ1. Transplantation. 65:98-98. 1998
- A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model. Journal of Immunology. 160:2531-2538. 1998
- Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination. Human gene therapy. Clinical development. 8:1355-1363. 1997
- Intramarrow Cytokine Gene Transfer by Adenoviral Vectors in Dogs. Human gene therapy. Clinical development. 8:545-553. 1997
- Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung.. American Journal of Pathology. 149:1395-1403. 1996
- IDENTIFICATION OF DONOR-DERIVED DENDRITIC CELL PROGENITORS IN BONE MARROW OF SPONTANEOUSLY TOLERANT LIVER ALLOGRAFT RECIPIENTS1,2. Transplantation. 60:1555-1559. 1995